Low platelet count (thrombocytopenia) can cause bleeding. When the immune system mistakenly attacks platelets, it’s called Immune Thrombocytopenia (ITP). Medical advancements offer various ways to increase platelet levels. As of April 15, 2026, treatments range from established to innovative small-molecule drugs.
Table of contents
Initial Management: Corticosteroids
For acute ITP, especially in urgent, life-threatening situations requiring rapid platelet increase, corticosteroids are the primary choice. Oral prednisone remains a cornerstone, quickly suppressing the immune response that destroys platelets.
Thrombopoietin Receptor Agonists (TPO-RAs)
TPO-RAs stimulate bone marrow to produce platelets, revolutionizing chronic ITP management:
- Romiplostim: FDA-approved TPO-RA, shown effective and safe, particularly for ITP patients aged 65 and older.
- Eltrombopag (Promacta): FDA-approved for adults, now expanded to children aged 1+ with chronic ITP.
- Lusutrombopag and Avatrombopag: Oral TPO-R agonists FDA-approved for thrombocytopenia in adults with chronic liver disease prior to procedures, demonstrating utility beyond ITP.
Other Key Therapeutic Classes
Beyond TPO-RAs, other platelet-increasing medications offer tailored approaches:
- Immunosuppressive Antimetabolites & Synthetic Antineoplastic Drugs: Modulate the immune system to reduce platelet destruction.
- Androgens: Less common now for ITP, but historically explored for hematopoietic stimulation.
- Monoclonal Antibodies: Targeted biological therapies modulating immune cell function or targeting cells responsible for platelet destruction.
- SYK Inhibitors: Fostamatinib, the first SYK inhibitor for ITP, blocks a key enzyme in immune-mediated platelet destruction.
- Bruton Tyrosine Kinase (BTK) Inhibitors: FDA has approved the first BTK inhibitor for ITP, a significant advancement targeting B-cell mediated autoimmunity pathways.
Emergency Treatment and Blood Products
For severe, life-threatening thrombocytopenia or active bleeding, emergency treatment includes blood products like platelet transfusions for rapid increase. This is usually temporary until definitive medical treatments work.
Managing low platelet counts, particularly in ITP, benefits from a diverse, evolving medication arsenal. From corticosteroids to TPO-R agonists, SYK, and BTK inhibitors, patients have many options to increase platelets and improve quality of life. Therapy choice depends on the individual condition, severity, and treatment response.
